Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Poespoprodjo, Jeanne Rini ^a,b   Fobia, Wendy ^b   Kenangalem, Enny ^a,b   Lampah, Daniel A ^a,b   Sugiarto, Paulus ^c   Tjitra, Emiliana ^d   Anstey, Nicholas M ^e,f   Price, Ric N ^e,f,g  

^a District Health Authority   (Indonesia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Mitra Masyarakat Hospital Indonesia   (Indonesia)

^d NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f ROYAL DARWIN HOSPITAL   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CLINDAMYCIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; QUININE;

ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; DELIVERY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MATERNAL CARE; MEDICAL HISTORY; MULTIDRUG RESISTANCE; PARASITEMIA; PERINATAL MORTALITY; PLASMODIUM VIVAX MALARIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION;

ACUTE DISEASE; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITEMIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREGNANCY OUTCOME; QUINOLINES;

EID: 84898426433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084976     Document Type: Article

References (29)

1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7: 93-104. (Pubitemid 46123132)
2. Brabin BJ, Hakimi M, Pelletier D (2001) An analysis of anemia and pregnancy-related maternal mortality. J Nutr 131: 604S-614S; discussion 614S-615S.
3. WHO/AFRO (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. World Health Organization Regional Office for Africa.
4. Nosten F, McGready R, Mutabingwa T (2007) Case management of malaria in pregnancy. Lancet Infect Dis 7: 118-125. (Pubitemid 46137945)
5. Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, et al. (2012) Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12: 75-88.
6. World Health Organisation (2010) Guidelines for the treatment of malaria.
7. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, et al. (2012) Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12: 388-396.
8. WHO (2010) Guidelines for the treatment of malaria. Geneva. pp. 16,28,29,38,39.
9. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, et al. (2008) Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 46: 1374-1381. (Pubitemid 351589936)
10. Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, et al. (2006) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1: 1-15.
11. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, et al. (2007) Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 101: 351-359. (Pubitemid 46205894)
12. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757-765. (Pubitemid 46335820)
13. Clark RL, White TE, S AC, Gaunt I, Winstanley P, et al. (2004) Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71: 380-394. (Pubitemid 40076263)
14. Clark RL, Arima A, Makori N, Nakata Y, Bernard F, et al. (2008) Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 83: 418-434.
15. Batty KT, Moore BR, Stirling V, Ilett KF, Page-Sharp M, et al. (2010) Investigation of reproductive toxicity of piperaquine in mice. Reprod Toxicol 29: 206-213.
16. Rijken MJ, McGready R, Boel ME, Barends M, Proux S, et al. (2008) Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 78: 543-545. (Pubitemid 351845153)
17. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, et al. (2012) Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 56: 1997-2007.
18. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, et al. (2008) Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J 7: 148.
19. Hidayat M (2001) Rapid Survey on Maternal Mortality in Papua Province. Provincial Health Office (PHO), Papua Indonesia.
20. Mimika DHO (2005) Mimika District Health Office Annual Statistics.
21. Shulman CE, Graham WJ, Jilo H, Lowe BS, New L, et al. (1996) Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. Trans R Soc Trop Med Hyg 90: 535-539. (Pubitemid 26356635)
22. WHO (1996) Catalogue of health indicators: a selection of important health indicators recommended by WHO programmes. Geneva. pp. 20 and 51.
23. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, et al. (1991) New Ballard Score, expanded to include extremely premature infants. J Pediatr 119: 417-423.
24. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, et al. (2007) Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 44: 1067-1074. (Pubitemid 46580274)
25. Hasugian AR, Tjitra E, Ratcliff A, Siswantoro H, Kenangalem E, et al. (2009) In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother 53: 1094-1099.
26. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, et al. (2004) Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57: 253-262. (Pubitemid 38296988)
27. Adam I, Tarning J, Lindegardh N, Mahgoub H, McGready R, et al. (2012) Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 87: 35-40.
28. McGready R, Thwai KL, Cho T, Samuel, Looareesuwan S, et al. (2002) The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 96: 180-184. (Pubitemid 34846564)
29. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3.